Neptune Product and Distribution Update(own tobe effective in cholesterol manage...)

Date:5/5/2009

own to be effective in cholesterol management, joint health, inflammation and cognitive function. Neptune Krill Oil NKO(R) represents the first and only clinically proven omega-3 phospholipids exhibiting unmatched safety, purity and stability. NKO(R) omega-3 marine phospholipids set a new standard of omega-3 excellence supported by a strong intellectual property portfolio and multinational regulatory approvals. Neptune pursues market opportunities in the nutraceutical markets (dietary supplement, functional food) and pharmaceutical markets (OTC, medical food, Rx) through its subsidiaries Acasti Pharma for cardiovascular applications and NeuroBioPharm for neurological applications. NASDAQ does not accept responsibility for the adequacy or accuracy of this press release. Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Statements in this press release that are not statements of historical or current fact, including statments relating to the Company's expectation regarding the future performance and marketability of its products, constitute "forward-looking statements" within the meaning of the U.S. Private Securities Litigation Reform Act of 1995 and Canadian securities laws. Such forward-looking statements involve known and unknown risks, uncertainties, and other unknown factors that could cause the actual results of the Company to be materially different from historical results or from any future results expressed or implied by such forward-looking statements. In addition to statements which explicitly describe such risks and uncertainties, readers are urged to consider statements labeled with the terms "believes," "belief," "expects," "intends," "anticipates,"should," "will" or "plans" to be uncertain and forward-looking. The forward-looking statements co
'/>"/>

SOURCE NEPTUNE TECHNOLOGIES & BIORESSOURCES INC. Copyright©2009 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4
Related biology technology :

1. Neptune Technologies to expect Record Revenues; Fiscal 2009 Third Quarter and Year-End Results
2. Human clinical study demonstrates superior Neptune Krill Oil NKO(R) pharmacokinetic profile
3. Acasti Pharma completes offer to exchange outstanding Neptune Technologies dividend notes
4. Neptune Technologies & Bioressources Inc. reports first quarter results
5. Neptune Technologies successfully completes $2.75 million private placement with 10% management participation
6. Neptune Technologies and Marine Life Sciences enter worldwide distribution alliance with Weider Global Nutrition
7. Neptune Krill Oil, NKO(R), enters WALGREENS, the largest U.S. retail pharmacy chain, under the brand name Schiff(R) MegaRed(TM)
8. Neptune Technologies decided not to re-price options
9. Neptune Technologies successfully completes up to $8.5 million debt financing with Desjardins Group
10. Neptune Technologies Reports Record Fiscal 2008 Fourth Quarter and Year End Results
11. Neptune Technologies & Bioressources Inc. reports third quarter results and update on strategic milestones